TheraRadar
Clinical-Stage Companies / Theracos

Theracos

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 8/1/2018

20
Total Trials
7
Phase 3
4
Phase 2
0
Recruiting
167
Score

Pipeline by Phase

Phase 3
7
Phase 2
4
Phase 1
10

Therapeutic Focus

Type 2 Diabetes Mellitus Type2 Diabetes Mellitus Diabetes Mellitus Type 2 Essential Hypertension Diabetes Mellitus

Clinical Trials (20)

NCT02558296 Phase 3 COMPLETED

Bexagliflozin Efficacy and Safety Trial

Started: 10/1/2015

NCT03259789 Phase 3 COMPLETED

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Started: 11/28/2017

NCT02836873 Phase 3 COMPLETED

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Started: 9/23/2016

NCT02715258 Phase 3 COMPLETED

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Started: 3/1/2016

NCT03115112 Phase 3 COMPLETED

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Started: 10/12/2017

NCT02769481 Phase 3 COMPLETED

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Started: 8/15/2016

NCT03514641 Phase 2 COMPLETED

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Started: 10/18/2017

NCT01377844 Phase 2 COMPLETED

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Started: 12/1/2011

NCT02390050 Phase 2 COMPLETED

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Started: 5/12/2015

NCT01029704 Phase 2 COMPLETED

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Started: 12/1/2009

NCT03197324 Phase 1 COMPLETED

Bexagliflozin Drug/Drug Interaction Study With Digoxin

Started: 7/24/2017

NCT02956044 Phase 1 COMPLETED

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Started: 11/1/2016

NCT03296800 Phase 1 COMPLETED

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Started: 9/27/2017

NCT02820298 Phase 1 COMPLETED

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Started: 6/20/2016

NCT03557658 Phase 1 COMPLETED

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

Started: 7/26/2018

NCT03167411 Phase 1 COMPLETED

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Started: 5/24/2017

NCT03417076 Phase 1 WITHDRAWN

Absolute Bioavailability Study With Bexagliflozin

Started: 8/1/2018

NCT01155531 Phase 1 COMPLETED

Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects

Started: 5/1/2010

NCT00924053 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

Started: 6/1/2009

NCT00854113 Phase 1 COMPLETED

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

Started: 2/1/2009

Drug Candidates

Bexagliflozin Bexagliflozin tablets, 20 mg EGT0001442 Bexagliflozin tablets Sertraline plus Telenzepine EGT0001474
Activity Status: Inactive
Last Trial Started: 8/1/2018
Last Trial Ended: 10/23/2019
Trials (12 months): 0
Completed Trials: 19
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.